Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1682
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18339126 | DETECTION OF EPIGENETIC STATUS USING SEQUENCE-SPECIFIC DEGRADATION | Non-Final OA | GUARDANT HEALTH, INC. |
| 18152042 | METHODS OF DETECTING GENOMIC REARRANGEMENTS USING CELL FREE NUCLEIC ACIDS | Non-Final OA | GUARDANT HEALTH, INC. |
| 18289455 | METHODS FOR DETECTING DYSFUNCTIONAL NK CELLS IN LEUKEMIA PATIENTS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18050071 | HIGHLY SPECIFIC CIRCULAR PROXIMITY LIGATION ASSAY | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18018101 | DE-CROSSLINKING COMPOUNDS AND METHODS OF USE FOR SPATIAL ANALYSIS | Non-Final OA | 10x Genomics, Inc. |
| 18036392 | SINGLE-CELL PROFILING OF CHROMATIN OCCUPANCY AND RNA SEQUENCING | Final Rejection | The United States of America, as represented by the Secretary, Dept. of Health and Human Services |
| 17929062 | ASSESSMENT OF MELANOMA THERAPY RESPONSE | Final Rejection | UNIVERSITY OF UTAH RESEARCH FOUNDATION |
| 18284131 | METHODS OF DETERMINING TREATMENT OUTCOME | Final Rejection | The Johns Hopkins University |
| 18268893 | DETECTION OF LUNG CANCER USING CELL-FREE DNA FRAGMENTATION | Final Rejection | The Johns Hopkins University |
| 17997905 | PREDICTING RESPONSE TO PD-1 AXIS INHIBITORS | Final Rejection | Hoffmann-La Roche Inc. |
| 17776741 | METHOD FOR DETECTING OR QUANTIFYING OLIGONUCLEOTIDE | Final Rejection | SEKISUI MEDICAL CO., LTD. |
| 18552397 | RELIABLE IDENTIFICATION OF REGIONS ('A SITES') IN COMPLEX RNA MOLECULES THAT ARE ACCESSIBLE TO NUCLEIC ACIDS OR COMPLEXES OF NUCLEIC ACIDS WITH ENDONUCLEASES | Non-Final OA | Martin-Luther-Universität Halle-Wittenberg |
| 18252524 | METHODS FOR THE ACCURATE DETECTION OF MUTATIONS IN SINGLE MOLECULES OF DNA | Non-Final OA | GENOME RESEARCH LIMITED |
| 17630304 | MOLECULAR CLASSIFIERS FOR PROSTATE CANCER | Final Rejection | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy